Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill
Khac Phu Nguyen
Tue, August 11, 2026 at 1:05 AM GMT+5:30
2 min read
- LLY
+3.85%
This article first appeared on GuruFocus
Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly’s blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 million in its latest reported quarter, versus the $105.6 million analyst estimate cited by Reuters. The U.K. approval expands the opportunity, but it does not automatically put Foundayo into patients’ hands. NHS reimbursement and broader commercial access still have to follow.
Is LLY fairly valued? Test your thesis with our free DCF calculator
That is where this gets interesting. Lilly does not need Foundayo to steal patients from Mounjaro or Zepbound. It needs the pill to make the market bigger. Some patients simply do not want injections, and a once-daily tablet removes that friction. Lilly already has the brand recognition, physician relationships and obesity-drug infrastructure to push a new format aggressively. But this will not be an uncontested runway. Novo Nordisk (NYSE:NVO) has oral Wegovy, turning the next GLP-1 battle into more than a race for weight-loss numbers. Convenience, pricing, supply, reimbursement and patient retention will matter. Lilly recently raised its 2026 revenue outlook to $85 billion to $87 billion, with Mounjaro and Zepbound doing much of the heavy lifting. If Foundayo develops into a third major franchise, Lilly’s growth machine gets another cylinder.
The valuation picture adds another twist. GuruFocus shows Lilly at $1,211.32 on Aug. 10 against a GF Value estimate near $1,500, putting the shares roughly 19.4% below that benchmark. That is a notable gap for a company already sitting at the center of one of pharma’s biggest growth markets. Still, approval alone will not close it. Foundayo now has to produce prescriptions, reimbursement wins and sustained demand. If Lilly can turn a GLP-1 pill into another blockbuster while Mounjaro and Zepbound keep charging ahead, investors are no longer looking at one obesity winner. They are looking at an increasingly powerful franchise built around multiple ways to capture the same enormous market.
